Diversified: Healthcare Services (Hospice Care) and Home Services (Plumbing & Drain Cleaning)
Strategic Profile
The company's business model combines stable, recession-resistant services in two distinct industries, providing diversification and consistent financial performance. Chemed reported service revenues and sales of $624.9 million for the third quarter of 2025 alone, with the majority of Chemed's revenue coming from its hospice operations, with total consolidated revenue of $624.9 million, with Vitas Healthcare contributing nearly two-thirds of that total.
Cyborg Score Rationale
Chemed demonstrates strong fundamentals through its diversified portfolio of recession-resistant services, consistent revenue generation, and market leadership in both segments. However, recent earnings guidance cuts and Medicare cap pressures in the VITAS segment indicate near-term headwinds affecting profitability growth.
Top Insights
Dual business model provides countercyclical revenue stability: healthcare (65% of revenue) balances with high-margin plumbing services (35%)
Recent earnings guidance cut to $22.00-$22.30 EPS reflects Medicare cap challenges and rising operational costs in VITAS segment
Roto-Rooter segment significantly more profitable with 22.7% EBITDA margin vs. VITAS at 17.0%, indicating margin divergence across segments
Long-tenured management team with 25+ year average tenure provides operational consistency while executing decentralized subsidiary strategy
Named Competitors
Amedisys — Large competitive hospice and home health provider
LHC Group — Major provider of home care and hospice services
ServiceMaster (Servicemaster Global Holdings) — Diversified home services provider with plumbing and restoration services
Franchise Plumbing Networks — Fragmented plumbing and drain cleaning market
Recent Developments
(November 2025) Q3 2025 revenue of $624.9M with Adjusted EPS of $5.27, down 6.6% YoY, reflecting profit margin compression
(2025) Guidance lowered from $24.95-$25.45 to $22.00-$22.30 EPS due to Medicare cap and operational challenges
(May 2025) Stock price at $569.11 with market cap approximately $8.4B
Open the full interactive Chemed Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.